Nautilus Biotechnology (NAUT) investor relations material

Executive summary

• Initiated Iterative Mapping Early Access Program, expanding access to Tau proteoform assay with Baylor College of Medicine as the first customer in an NIH-funded cancer study.

• Advanced Tau proteoform sample processing and analysis, supporting platform validation and future publications.

• Appointed a new VP of Global Sales to drive Early Access customer expansion and Voyager platform adoption ahead of commercial launch.

Financial highlights

• Operating expenses decreased 14% year-over-year to $16.1 million for Q1 2026, primarily due to lower salaries, benefits, stock-based compensation, and facilities costs.

• Net loss narrowed to $14.7 million in Q1 2026 from $16.6 million in Q1 2025.

• Cash, cash equivalents, and investments totaled $143.4 million as of March 31, 2026.

• Interest income for Q1 2026 was $1.4 million, down from $2.2 million in Q1 2025.

• Net loss per share was $0.12, compared to $0.13 in the prior year period.

Capital allocation and financing

• Net cash used in operating activities was $13.1 million for Q1 2026, compared to $13.9 million in Q1 2025.

• Net cash provided by investing activities was $14.2 million, primarily from maturities of securities.

• Net cash provided by financing activities was $1.1 million, mainly from stock option exercises.